IL243638B - Composition for the management of nausea and vomitting - Google Patents

Composition for the management of nausea and vomitting

Info

Publication number
IL243638B
IL243638B IL243638A IL24363816A IL243638B IL 243638 B IL243638 B IL 243638B IL 243638 A IL243638 A IL 243638A IL 24363816 A IL24363816 A IL 24363816A IL 243638 B IL243638 B IL 243638B
Authority
IL
Israel
Prior art keywords
nausea
vomiting
preparations
treatment
Prior art date
Application number
IL243638A
Other languages
English (en)
Hebrew (he)
Other versions
IL243638A0 (en
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL243638(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of IL243638A0 publication Critical patent/IL243638A0/en
Publication of IL243638B publication Critical patent/IL243638B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
IL243638A 2013-07-22 2016-01-17 Composition for the management of nausea and vomitting IL243638B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856971P 2013-07-22 2013-07-22
PCT/CA2014/050231 WO2015010194A1 (en) 2013-07-22 2014-03-13 Composition for the management of nausea and vomiting

Publications (2)

Publication Number Publication Date
IL243638A0 IL243638A0 (en) 2016-02-29
IL243638B true IL243638B (en) 2019-09-26

Family

ID=50877783

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243638A IL243638B (en) 2013-07-22 2016-01-17 Composition for the management of nausea and vomitting

Country Status (28)

Country Link
US (3) US10028941B2 (enExample)
EP (1) EP3024466B1 (enExample)
JP (1) JP6379194B2 (enExample)
KR (1) KR102242391B1 (enExample)
CN (1) CN105492013B (enExample)
AR (1) AR097023A1 (enExample)
AU (1) AU2014295765B2 (enExample)
BR (1) BR112016001474A2 (enExample)
CA (1) CA2847022C (enExample)
CL (1) CL2016000154A1 (enExample)
CY (1) CY1120386T1 (enExample)
DK (1) DK3024466T3 (enExample)
EA (1) EA029690B1 (enExample)
ES (1) ES2670619T3 (enExample)
HU (1) HUE039131T2 (enExample)
IL (1) IL243638B (enExample)
MX (1) MX366760B (enExample)
MY (1) MY191347A (enExample)
NO (1) NO3086669T3 (enExample)
NZ (1) NZ716017A (enExample)
PL (1) PL3024466T3 (enExample)
PT (1) PT3024466T (enExample)
SA (1) SA516370443B1 (enExample)
SG (1) SG11201600122RA (enExample)
TW (2) TWI654977B (enExample)
UY (1) UY35674A (enExample)
WO (1) WO2015010194A1 (enExample)
ZA (1) ZA201600383B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5914701B2 (ja) 2012-02-22 2016-05-11 デュシネイ・インコーポレイテッド ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US10244873B2 (en) 2015-10-01 2019-04-02 Isee Store Innovations, Llc Adjustable product display system and method
WO2024180559A1 (en) * 2023-03-01 2024-09-06 Akums Drugs & Pharmaceuticals Limited A stable tablet-in-tablet composition for nausea vomiting in pregnancy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ286242A (en) 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000059481A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6514481B1 (en) 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
DE60219607T2 (de) 2001-01-09 2007-12-27 Microchips, Inc., Bedford Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
AU2003303288B2 (en) 2002-08-16 2006-12-07 Microchips, Inc. Controlled release device and method
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
ATE424928T1 (de) 2004-09-01 2009-03-15 Microchips Inc Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
KR101190708B1 (ko) 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
US9884022B2 (en) 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
CN103037849A (zh) 2010-06-22 2013-04-10 安成国际药业股份有限公司 具有减少的食物效应的控释组合物
CN103402502A (zh) 2011-02-14 2013-11-20 宝洁公司 包衣中包含蜂蜜的膜包衣固体剂型
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
JP5914701B2 (ja) 2012-02-22 2016-05-11 デュシネイ・インコーポレイテッド ドキシラミンおよびピリドキシン、ならびに／またはその代謝物もしくは塩の製剤
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów

Also Published As

Publication number Publication date
EP3024466A1 (en) 2016-06-01
CA2847022C (en) 2015-04-07
EA029690B1 (ru) 2018-04-30
MY191347A (en) 2022-06-17
PT3024466T (pt) 2018-07-13
EA201690149A1 (ru) 2016-06-30
CL2016000154A1 (es) 2016-08-05
JP6379194B2 (ja) 2018-08-22
TW201720442A (zh) 2017-06-16
US20150025033A1 (en) 2015-01-22
KR102242391B1 (ko) 2021-04-21
HUE039131T2 (hu) 2018-12-28
MX2016000884A (es) 2016-05-05
EP3024466B1 (en) 2018-04-04
ES2670619T3 (es) 2018-05-31
NO3086669T3 (enExample) 2018-06-23
PL3024466T3 (pl) 2018-08-31
TW201513860A (zh) 2015-04-16
US10028941B2 (en) 2018-07-24
HK1218264A1 (en) 2017-02-10
SG11201600122RA (en) 2016-02-26
UY35674A (es) 2014-12-31
BR112016001474A2 (pt) 2020-04-14
JP2016527237A (ja) 2016-09-08
MX366760B (es) 2019-07-23
KR20160033201A (ko) 2016-03-25
DK3024466T3 (en) 2018-06-06
CN105492013B (zh) 2018-09-18
CN105492013A (zh) 2016-04-13
TWI589292B (zh) 2017-07-01
US20160143892A1 (en) 2016-05-26
NZ716017A (en) 2020-07-31
EP3024466A4 (en) 2017-03-29
WO2015010194A1 (en) 2015-01-29
AU2014295765B2 (en) 2019-02-14
CY1120386T1 (el) 2019-07-10
US9452181B2 (en) 2016-09-27
SA516370443B1 (ar) 2018-08-08
US9439920B2 (en) 2016-09-13
ZA201600383B (en) 2017-11-29
AR097023A1 (es) 2016-02-10
TWI654977B (zh) 2019-04-01
US20150025032A1 (en) 2015-01-22
AU2014295765A1 (en) 2016-02-04
CA2847022A1 (en) 2014-06-03
IL243638A0 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
IL289821B (en) Compositions and methods for immunotherapy
IL281549A (en) Compositions and methods for growth factor modulation
HUS2400023I1 (hu) Készítmények és módszerek anémia kezelésére
GB2513167B (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
IL285527A (en) Compositions and methods for immunotherapy
CL2016001477A1 (es) Anticuerpos e inmunoconjugados anti-cd33
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
HRP20181580T1 (hr) Pripravci cftr irnk i povezani postupci i upotrebe
EP3164406C0 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
LT3121164T (lt) Sulfamoilpirolamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
HUE041224T2 (hu) Deferasziroxot tartalmazó orális készítmények
LT3007726T (lt) Tautopatijos gydymo būdai
IL242137B (en) Methods and compositions for wound healing
HUE060909T2 (hu) Mûtrágya készítmények
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
IL242795B (en) Compositions, methods, and devices for dialysis
DK3068505T3 (da) Spillesystem og -fremgangsmåde
LT2991633T (lt) Terapija bakteriografu
HRP20181122T1 (hr) Postupak za pripremu jopamidola
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények
IL245167B (en) Slow-release solid oral compositions
IL244881B (en) Hiv treatment formulation of atazanavir and cobicistat
IL243638A0 (en) Composition for the management of nausea and vomitting
LT3079667T (lt) Farmacinės vaisto formos

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed